<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04380922</url>
  </required_header>
  <id_info>
    <org_study_id>PO20062*</org_study_id>
    <nct_id>NCT04380922</nct_id>
  </id_info>
  <brief_title>Prevalence of Periodontal Diseases in IBD</brief_title>
  <acronym>MICIMaP</acronym>
  <official_title>Prevalence of Periodontal Diseases in Inflammatory Bowel Diseases : a Pilot-study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHU de Reims</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CHU de Reims</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Periodontal diseases are highly prevalent inflammatory diseases. It is now well known that&#xD;
      they are correlated with numerous systemic diseases as : diabetes, chronic obstructive&#xD;
      pulmonary disease, metabolic syndrome or rheumatoid arthritis. Recently, periodontal diseases&#xD;
      have been correlated with inflammatory bowel diseases (IBD). IBD include two types, Crohn's&#xD;
      disease and Ulcerative Colitis. It could be a significant risk factor for the pathogenesis of&#xD;
      periodontal disease. These diseases present common features : a high prevalence worldwide,&#xD;
      multifactorial pathogenies with common mechanisms. To date, no study has linked activity of&#xD;
      IBD and periodontal diseases. The authors hypotheses that the prevalence of periodontal&#xD;
      diseases could be increased in patient presenting an active IBD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study explores the prevalence of periodontal diseases regarding to the activity&#xD;
      status of IBD (active versus non-active).&#xD;
&#xD;
      Diseases activity will be assessed by HBI (Crohn's disease) or partial Mayo score (Ulcerative&#xD;
      Colitis) associated with fecal calprotectin and/or CRP and/or inflammatory/ulcerative&#xD;
      lesions.&#xD;
&#xD;
      Periodontal diseases (periodontitis and gingivitis) will be diagnosed according to the&#xD;
      international classification of periodontal diseases (Chicago 2017) and based on the&#xD;
      decision-making algorithms by Tonetti and Sanz. A periodontal screening, socio-demographic&#xD;
      data and clinical data will be collected. Then, oral mucosa dermatological manifestations&#xD;
      relative to IBD, treatment need (ICDAS) and quality of life related to oral health (GOHAI)&#xD;
      will be evaluated. These data will be collected by a periodontist.&#xD;
&#xD;
      The principal hypothesis of this study is that the prevalence of periodontal diseases could&#xD;
      be increased in patient presenting an active IBD.&#xD;
&#xD;
      The primary objective is to evaluate if patients presenting active IBD present more stage III&#xD;
      and IV periodontal diseases than non-active IBD ones.&#xD;
&#xD;
      The second objectives are :&#xD;
&#xD;
        -  to compare periodontal diseases, gingivitis and oral mucosa dermatological&#xD;
           manifestations rates according to the diseases activity, the IBD type and the treatment&#xD;
           used to treat IBD,&#xD;
&#xD;
        -  to compare oral treatment need according to the activity and the type of IBD,&#xD;
&#xD;
        -  to compare quality of life related to oral health according to the activity and the type&#xD;
           of IBD&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Periodontal Disease</measure>
    <time_frame>Day 0</time_frame>
    <description>Periodontal Disease will be diagnosed according to the new classification of periodontal diseases (Chicago, 2017) and defined by the decision-making algorithms (Tonetti and Sanz, 2019). Diagnosis will be based on Buccal or lingual Clinical attachment level (CAL), Recession (REC) and Periodontal Pocket Depths (PPD) measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Gingivitis</measure>
    <time_frame>Day 0</time_frame>
    <description>Gingivitis will be diagnosed according to the new classification of periodontal diseases (Chicago, 2017) and defined by the decision-making algorithms (Tonetti and Sanz, 2019). Bleeding On Probing (BOP) higher than 10% is considered as a Gingivitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral mucosa dermatological manifestations secondary to IBD</measure>
    <time_frame>Day 0</time_frame>
    <description>Defined by WHO criteria (2013)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral Health Quality of Life</measure>
    <time_frame>Day 0</time_frame>
    <description>GOHAI validated in French for general population -Tubert-Jeanin et al., 2003)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral treatment need</measure>
    <time_frame>Day 0</time_frame>
    <description>Evaluated by ICDAS (International Caries Detection and Assessment Score) (Ismaïl et al., 2007)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Periodontal Diseases</condition>
  <arm_group>
    <arm_group_label>Active IBD</arm_group_label>
    <description>Active Inflammatory Bowel Diseases defined as :&#xD;
For Crohn's disease :&#xD;
Harvey Bradshaw Index ≥ 4&#xD;
Associated with fecal calprotectin rate &gt; 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy or in imaging within 3 months For Ulcerative colitis&#xD;
Partial Mayo score ≥ 2&#xD;
Associated with fecal calprotectin rate &gt; 250 µg/g within 3 months OR CRP ≥ 6mg /L OR the presence of ulcerative and/or inflammatory lesions in endoscopy within 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-active IBD</arm_group_label>
    <description>Non-active Inflammatory Bowel Diseases</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Periodontal screening</intervention_name>
    <description>Periodontal data collection (PPD, REC, CAL)</description>
    <arm_group_label>Active IBD</arm_group_label>
    <arm_group_label>Non-active IBD</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients consulting for the management of Crohn's disease or Ulcerative colitis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients&#xD;
&#xD;
          -  consulting Gastroenterology departments in the university hospital of Reims or&#xD;
             Amiens-Picardie for the management of Crohn's disease or Ulcerative colitis&#xD;
&#xD;
          -  signed informed consent form&#xD;
&#xD;
          -  affiliated to the French Social Security system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients presenting:&#xD;
&#xD;
          -  a medical history likely to compromise protocol (psychiatric disorders, other&#xD;
             inflammatory diseases, antibiotics, NSAIDs within the last 3 months)&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Inflammatory rheumatism&#xD;
&#xD;
          -  Cancer or radiotherapy up to5 years before inclusion&#xD;
&#xD;
          -  X-ray therapy in the area of interest&#xD;
&#xD;
          -  Pregnancy or Breastfeeding&#xD;
&#xD;
          -  Eating disorders&#xD;
&#xD;
          -  Patients under legal protection, trusteeship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Johan SERGHERAERT</last_name>
    <phone>0326787878</phone>
    <email>jsergheraert@chu-reims.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Guillaume CADIOT</last_name>
    <phone>0326787878</phone>
    <email>gcadiot@chu-reims.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chu Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien JOLLY</last_name>
      <phone>326788472</phone>
      <phone_ext>33</phone_ext>
      <email>djolly@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 5, 2020</study_first_submitted>
  <study_first_submitted_qc>May 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>June 7, 2021</last_update_submitted>
  <last_update_submitted_qc>June 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

